Track topics on Twitter Track topics that are important to you
The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might...
Original Article: Shire May Spin Out Neuroscience Unit To Tighten Rare Disease FocusNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...